Clinically Relevant Laboratory Monitoring of Gender-Affirming Hormone Therapy in Transgender People—Experiences from a Teaching Hospital in the Netherlands
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfae006 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Nadine Pouw und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Chemistry, MaasstadLab, Maasstad Hospital, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Transgender Persons, Testosterone, Estradiol, Hospitals, Teaching. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Transgender care is shifting from academic to nonacademic settings leading to use of common (immunoassay) compared to sophisticated (mass spectrometry) methods to monitor estradiol and testosterone during gender-affirming hormone therapy (GAHT). The type of assay can influence results and have significant implications for clinical decision making. An evidence gap is present in recommendations regarding the assay needed to monitor GAHT. The present study aimed to summarize current evidence and evaluate immunoassay estradiol and testosterone concentrations in transgender people visiting a nonacademic hospital for GAHT.
Methods
Clinical practice guidelines on GAHT and scientific literature on assay methodologies were screened and summarized. Laboratory and medical data from 252 patients who visited the transgender outpatient clinic of the Maasstad Hospital for GAHT between 2020 and 2022 were retrospectively analyzed.
Results
Our research showed that the most used clinical practice guidelines for GAHT provide hormonal target values without recommending a preferred method. A comprehensive literature search on agreement between immunoassay and mass spectrometry showed substantial heterogeneity in results. Retrospective analysis of our immunoassay measured data in transgender people showed hormonal changes during GAHT that are to be expected from the medication used.
Conclusions
We demonstrate that laboratory monitoring of GAHT in a nonacademic hospital can be done safely by immunoassay in most cases. Only in cases where clinical observation is discordant with the hormonal results do more sophisticated methods need to be deployed. A best practice model was proposed for transgender care in nonacademic hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Chemistry, MaasstadLab, Maasstad Hospital, Rotterdam, the Netherlands.
- Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
ORCID-Profile: Nadine Pouw, Snježana Kos
Zitieren
APA
Pouw, N., van der Linden, J., Teuben, S., & Kos, S. (2024). Clinically Relevant Laboratory Monitoring of Gender-Affirming Hormone Therapy in Transgender People—Experiences from a Teaching Hospital in the Netherlands. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae006
Vancouver
Pouw N, van der Linden J, Teuben S, Kos S. Clinically Relevant Laboratory Monitoring of Gender-Affirming Hormone Therapy in Transgender People—Experiences from a Teaching Hospital in the Netherlands. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae006
BibTeX
@article{Pouw2024,
author = {Pouw, Nadine and van der Linden, Joke and Teuben, Sonja and Kos, Snježana},
title = {Clinically Relevant Laboratory Monitoring of Gender-Affirming Hormone Therapy in Transgender People—Experiences from a Teaching Hospital in the Netherlands},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfae006}
}
EUVIMED